Improving surveillance of antibiotic-resistant Pseudomonas aeruginosa in Europe

• Antonio Oliver, Hospital Son Espases-IdISBa, Spain (Coordinator)
• Thierry Naas, Hopital de Bicêtre, France (Observer)
• Iva Butic, University Hospital for Infectious diseases “Dr. Fran Mihaljevic”, Croatia (Observer)
• Luis Martínez Martínez, Hospital Universitario Reina Sofía, Spain (Observer)
• Cansu Cimen, University of Oldenburg, Germany (Observer)
• Yesmin Besli, Amerikan Hastanesi, Turkey (Observer)
• Christian Giske, Karolinska Institutet, Sweden (Observer)
• Jorge Arca Suárez, Instituto de Investigación Biomédica A Coruña- Complexo Hospitalario Universitario A Coruña, Spain (Observer)
• Onur Karatuna, EUCAST Development Laboratory for Antimicrobial Susceptibility Testing of bacteria, Sweden (Observer)
• Surbhi Malhotra-Kumar, University of Antwerp, Belgium (Observer)
• Mateja Pirs, University of Ljubljana, Slovenia (Observer)
• Marija Gužvinec, University Hospital for Infectious diseases “Dr. Fran Mihaljevic”, Croatia (Observer)
• Josip Ujevic, University Hospital for Infectious diseases “Dr. Fran Mihaljevic”, Croatia (Observer)
• Tíscar Graells, Royal Swedish Academy of Sciences, Sweden (Observer)
• Marko Jelic, University Hospital for Infectious diseases “Dr. Fran Mihaljevic”, Croatia (Observer)
• Arjana Tambic Andraševic, University Hospital for Infectious diseases “Dr. Fran Mihaljevic”, Croatia (Observer)
• Rossitza Vatcheva-Dobrevska, University Hospital "Queen Joanna", Bulgaria (Observer)
• Astra Vitkauskiene, Lithuanian University of Health Sciences, Lithuania (Observer)
• Astra Dambrauskiene, Hospital of Lithuanian University of Health Sciences Kauno klinikos, Lithuania (Observer)
• Dora Szabó, Semmelweis University, Hungary (Observer)
• Te-Din Daniel Huang, CHU UCL Namur NRC for MDR Enterobacterales, Pseudomonas and Acinetobacter, Belgium (Observer)
• Olivier Denis, CHU UCL Namur NRC for MDR Enterobacterales, Pseudomonas and Acinetobacter, Belgium (Observer)
• Pierre Bogaerts, CHU UCL Namur NRC for MDR Enterobacterales, Pseudomonas and Acinetobacter, Belgium (Observer)
• Rafael Canton, Instituto Ramón y Cajal de Investigación Sanitaria, Spain (Observer)
• Béla Kocsis, Semmelweis University, Hungary (Observer)
• Patricia Alexandra Curado Quintas Diniz Poeta, University of Trás-OS-Montes and Alto Douro, Portugal (Observer)
• Estrella Rojo-Molinero, Hospital Universitario Son Espases, Spain (Observer)
• Carla López-Causapé, Hospital Universitario Son Espases, Spain (Observer)
• Katy Jeannot, French National Reference Centre for Antibiotic Resistance in Pseudomonas & Acinetobacter, France (Observer)
• Jesús Oteo Iglesias, Centro Nacional de Microbiología, Spain (Observer)
• Laurent Poirel, University of Fribourg, Switzerland (Observer)
• Tomislav Kostyanev, Laboratoire national de santé, Luxembourg (Observer)
• Peter Croughs, Erasmus MC University Medical Center, Netherlands (Observer)
• Bogdan Iorga, Institut de Chimie des Substances Naturelles, France (Observer)
• Arnfinn Sundsfjord, The Arctic University of Norway, Norway (Observer)
• Torunn Pedersen, The Arctic University of Norway, Norway (Observer)
• Annarita Mazzariol, University of Verona, Italy (Observer)
• Andreas Kronenberg, Swiss Antibiotic Resistance Centre, Switzerland (Observer)

Pseudomonas aeruginosa is one of the top resistance threats world-wide, for which the situation is classified as critical by the World Health Organization. The growing prevalence of nosocomial infections produced by multidrug-resistant P. aeruginosa strains is indeed associated with significantly increased morbidity and mortality, since it compromises the available effective therapeutic options, even those recently introduce, due to emerging resistance mechanisms. In summary antibiotic resistance in P. aeruginosa is a severe, complex, continuously evolving threat in Europe and therefore coordinated efforts should be established to improve its surveillance and control. The network Improving surveillance of antibiotic-resistant Pseudomonas aeruginosa in Europe (ISARPAE) gathers 37 researchers from 17 European countries, including multiple national reference centres on P. aeruginosa antibiotic resistance..Thus the specific objectives of this network will be: 1. Create a forum of experts and researchers working on P. aeruginosa antimicrobial resistance to define the focus, procedures strategies and priorities for surveillance. 2.Training clinical microbiologists, infectious diseases physicians and researchers across Europe: Hands on workshop on Pseudomonas aeruginosa resistance phenotypes and whole genome sequence resistome analysis. 3. Provide advice, support and mentorship to less experienced or lower resources laboratories in Europe. 4. Develop the basis for a coordinated action with relevant stakeholders at European level, including future EU research grants applications.